By their own admission, it's a beautiful day for neurologists who have been working on Alzheimer's disease for several decades.
This Wednesday were published in the
New England Journal of Medicine
the results of a clinical trial evaluating the effectiveness of a monoclonal antibody, lecanemab, in slowing the progression of the disease.
Even if the effectiveness is measured, and is accompanied by significant adverse effects, this positive effect, unseen for 30 years, opens the way to a new era of treatments, comment the experts.
Prime Macron 2022: conditions, amount, date of payment... how does it work?
Alzheimer's disease is extremely painful for patients and their loved ones in that it is currently impossible to stop its progression until the patient loses his cognitive faculties and his autonomy.
However, lecanemab, co-developed by two laboratories, the Japanese Eisai and the American Biogen, shows for the first time a significant and constant effect on the evolution of the disease.
Read alsoAlzheimer's: genetics opens up new avenues of understanding
Immunotherapy was given for 18 months to…
This article is for subscribers only.
You have 81% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT